CoagClinic's Principles and Methodologies Helps The Ohio State University Medical Center Outperform All Other Academic Medical Centers in 2009 UHC Anticoagulation Benchmarking Project
Posted on: Thursday, 1 October 2009, 06:30 CDT
WESTPORT, Conn., Oct. 1 /PRNewswire/ -- Dr. Mark Wurster from The Ohio State University Medical Center presented his findings at the September 29th meeting of the University Health Consortium's Fall Forum. According to Dr. Wurster, "OSU is the only organization out of 31 participants in the UHC benchmarking study that qualified for better performance status. OSUMC showed excellent results and achieved above the UHC mean in every area of managing anticoagulation therapy with the use of critical laboratory studies. The system used in the UHC trial was developed using principles found in CoagClinic(TM), a commercially available software application."
Dr. Wurster's OSUMC team surpassed the UHC study group (n=42 vs. n=1211) in the following key performance areas:
1) Obtaining baseline and ongoing laboratory studies (85.7% vs. 76.8%) 2) Target range for INR on record at time of initiation of warfarin (64.3% vs. 29.3%) 3) Adjusting anticoagulation therapy based on laboratory studies where an aPTT was drawn greater than or equal to 4 and less than or equal to 8 hours after the first dose of UF heparin (83.3% vs. 59.6%) 4) Documenting the following education elements on discharge (77.8% vs. 50.3%): a. One of the following three: 1) appointment scheduled with PCP 2) explanation of need for laboratory test follow-up 3) referral to a coagulation clinic b. One of the following two: 1) signs and symptoms of bleeding 2) bleeding risk associated with anticoagulation c. Potential for adverse drug reactions and interactions with all home medicationsWurster's team also demonstrated excellent patient outcomes with a 0% rate of 30 day readmission and return to ED associated with anticoagulation therapy as well as low rates of bleeding or thromboembolic events (OSUMC 11.9% vs. UHC 26.2%.) No deaths occurred in Wurster's group during anticoagulation therapy upon admission.
About Mark Wurster, MD, FACP
Assistant Clinical Professor - Ohio State University
Lead Physician, Joint Commission Anticoagulation Task Force, Ohio State University Medical Center
Steering Committee for National Inpatient Benchmarking Project, University Health Consortium
Member, Anticoagulation Scientific Advisory Board, Roche Diagnostics
Chief Medical Officer, Standing Stone, Inc.
About Standing Stone Inc. CoagClinic(TM)
Standing Stone, based in Westport, CT, serves over 500 hospitals and clinics throughout the US and has been developing sophisticated best in class clinical workflow, decision support, billing data and outcomes measurement tools as contemplated by the HITECH Act for over a decade. Visit www.standingstoneinc.com to learn more about our best in class clinical decision support management tools and new HITECH Warranty.
SOURCE Standing Stone
Source: PR Newswire
Related Articles
- Integral Systems Congratulates NASA and the Johns Hopkins University Applied Physics Laboratory MESSENGER Team on its Successful Flyby of the Planet Mercury
- Cosentino(R) North America and Marble and Granite Works Donate Silestone(R) Natural Quartz and Eco(TM) Countertops for Universal Design Living Laboratory National Demonstration Home in Columbus, Ohio
- Vivisimo Powers Search to More Than 4,000 Employees at the Johns Hopkins University Applied Physics Laboratory
- Diplomat Specialty Pharmacy Tapped By Teva Neuroscience for Therapy Optimization Study for Multiple Sclerosis (TOP MS)
- New Way to Control Protein Activity Could Lead to Cancer Therapies, Stanford Study Shows
- VMware Announces vClient Initiative to Expand Virtual Desktops to Universal Clients - Desktops That Follow the User to Any Location
- BioServe Partners With Harvard and University of Michigan on Landmark Public Health Study
- Gilead Cystic Fibrosis Therapy Meets Study Goal
- Comcast, Discovery Networks and the Johns Hopkins University Applied Physics Laboratory Help More Than 100 Students Study the Sun
- Lipid-Modifying Therapy and Attainment of Cholesterol Goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) Study
 |
 |
User Comments (0)
RSS Feeds